DÜSSELDORF, Germany--(BUSINESS WIRE)--Ventac Partners announces today that it has successfully facilitated the completion of Miacom Diagnostic’s management buyout from the German-Finnish investor Inveni Capital Oy. As of the end of January, 2013, the majority of the company is owned and controlled by its current management team. The successful transaction facilitated by Ventac Partners new Düsseldorf office continues the firm’s stellar track record of molding life science, technology companies into viable commercial entities.
Miacom specializes in IVD tests for detecting acute systemic diseases, such as sepsis and pneumonia. The company, headquartered in Düsseldorf, Germany, was founded in 2006 with a promising core technology and a vision to apply it toward faster and better methods to identify pathogens and determine their resistance to antibiotics. Inveni Capital’s investment has funded the development and commercialization of the company’s initial molecular diagnostic product line currently sold in the European market.
Commenting on the transaction, Miacom’s Chief Executive Officer, Mirko Stange, Ph.D., said: “Private ownership is a very attractive solution to increase our flexibility, enabling the company to quickly address a fast-growing market in Europe and to prepare for product commercialization in the U.S. We´ve realized that focus and nimbleness are the keys to successfully capitalize on the diagnostic window of opportunity in front of us.”
An undisclosed, private investor will continue to support the company in its global sales expansion. “Miacom diagnostics is now poised to capitalize on the European opportunity before it and is well prepared for the planned infrastructure construction in the U.S.“, according to Nicole Groth, consultant at Ventac Partners.
About Ventac Partners
Ventac Partners is a dedicated life science consulting firm with offices in Europe, USA, and Asia that advises innovative Biotech companies in a wide range of strategic matters from company analysis up to exit strategies.
About miacom diagnostics (www.miacom-diagnostics.de)
miacom diagnostics specializes in in vitro diagnostic tests for pathogens causing acute systemic diseases. All kits enable simultaneous detection of the most-clinically relevant pathogens directly from specimens, and deliver results within 30 minutes. miacom has already commercialized several rapid tests for the European market, including diagnostics for the most-important systemic infectious diseases such as sepsis and pneumonia. All kits are designed as affordable multiplex tests that detect up to 14 different bacterial or fungal targets on a single microscope slide. In addition, miacom offers tests that detect a single pathogen such as S. aureus from a positive blood culture. In this test format, up to four patient probes can be processed on a single microscope slide to facilitate faster batch runs.